Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a report released on Monday.
A number of other equities research analysts also recently issued reports on the stock. Wedbush cut their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Wednesday, August 7th. Leerink Partnrs raised Voyager Therapeutics to a "strong-buy" rating in a research report on Wednesday, October 16th. Leerink Partners began coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an "outperform" rating and a $15.00 price objective on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Voyager Therapeutics presently has an average rating of "Buy" and an average price target of $17.00.
View Our Latest Stock Report on Voyager Therapeutics
Voyager Therapeutics Price Performance
Voyager Therapeutics stock traded down $0.25 during trading hours on Monday, hitting $5.39. The stock had a trading volume of 572,178 shares, compared to its average volume of 642,887. The stock has a market capitalization of $294.46 million, a price-to-earnings ratio of 7.94 and a beta of 0.89. The stock's fifty day moving average is $6.62 and its two-hundred day moving average is $7.49. Voyager Therapeutics has a 1-year low of $5.38 and a 1-year high of $11.72.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the previous year, the firm earned ($0.59) earnings per share. As a group, sell-side analysts anticipate that Voyager Therapeutics will post -1.12 EPS for the current year.
Insider Buying and Selling
In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at $500,525.82. The trade was a 6.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.53% of the stock is owned by company insiders.
Institutional Trading of Voyager Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. Ameritas Investment Partners Inc. grew its stake in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company's stock valued at $37,000 after acquiring an additional 1,300 shares during the period. Plato Investment Management Ltd purchased a new stake in Voyager Therapeutics in the 1st quarter valued at about $38,000. China Universal Asset Management Co. Ltd. grew its stake in Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock worth $61,000 after purchasing an additional 4,098 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Voyager Therapeutics during the 2nd quarter worth $85,000. Finally, ProShare Advisors LLC purchased a new position in Voyager Therapeutics during the 1st quarter valued at about $101,000. Institutional investors own 48.03% of the company's stock.
Voyager Therapeutics Company Profile
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Further Reading
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
